Bihua Chen
Sits on 5 boards. Overboarded · 5 public boards Last updated September 28, 2026
Time on boards
- Boards served
- 5
- Current seats
- 5
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 5 boards, counting each seat separately. Longest: Biomea Fusion Inc., 3 years.
Biomea Fusion Inc.
Director
Erasca Inc.
Director
BridgeBio Oncology Therapeutics Inc.
Director · CEO and Chairperson
Helix Acquisition Corp. III
Director · Chairperson and CEO
BlossomHill Therapeutics Inc.
Director
Chief executive roles
Helix Acquisition Corp. III
· Chairperson and CEO
Since January 2026
BridgeBio Oncology Therapeutics Inc.
· CEO and Chairperson
2024 – 2025
· Former
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 1, 2026 | BridgeBio Oncology Therapeutics Inc. | Other | −4,528,186 | — | — |
| Jul 1, 2026 | BridgeBio Oncology Therapeutics Inc. | Other | +2,692,459 | — | — |
| Jul 1, 2026 | BridgeBio Oncology Therapeutics Inc. | Other | +1,704,862 | — | — |
| Jul 1, 2026 | BridgeBio Oncology Therapeutics Inc. | Other | +130,865 | — | — |
| Jan 26, 2026 | Helix Acquisition Corp. III | Grant or award | +497,500 | $10.00 | $4,975,000 |
| Dec 11, 2025 | Corbus Pharmaceuticals Holdings Inc. | Open-market sale | −30,029 | $11.46 | $344,132 |
| Aug 11, 2025 | BridgeBio Oncology Therapeutics Inc. | Option exercise | +4,172,126 | — | — |
| Aug 11, 2025 | BridgeBio Oncology Therapeutics Inc. | Sold back to the company | −152,940 | — | — |
| Aug 11, 2025 | BridgeBio Oncology Therapeutics Inc. | Grant or award | +760,496 | $10.72 | $8,152,517 |
| Aug 11, 2025 | BridgeBio Oncology Therapeutics Inc. | Grant or award | +639,110 | $10.72 | $6,851,259 |
| Aug 11, 2025 | BridgeBio Oncology Therapeutics Inc. | Grant or award | +5,598,425 | $10.72 | $60,015,116 |
| Aug 11, 2025 | BridgeBio Oncology Therapeutics Inc. | Grant or award | +1,905,046 | — | — |
| Aug 11, 2025 | BridgeBio Oncology Therapeutics Inc. | Grant or award | +1,762,760 | — | — |
| Aug 11, 2025 | BridgeBio Oncology Therapeutics Inc. | Grant or award | +284,571 | — | — |
| Feb 14, 2025 | Aardvark Therapeutics Inc. | Derivative conversion | +800,189 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.